CRISPR-engineered T cells in Patients with Refractory Cancer
Genetically-edited immune cells can persist, thrive, and function months after a cancer patient receives them, according to new data published in Science by researchers from the Abramson Cancer Center.
Read moreCRISPR-engineered T cells in patients with refractory cancer
Genetically-edited immune cells can persist, thrive, and function months after a cancer patient receives them, according to new data published by researchers from the Abramson Cancer Center.
Gilteritinib induces differentiation in relapsed and refractory FLT3-mutated acute myeloid leukemia
An image from this article is featured on the cover of this edition of Blood Advances, a semimonthly medical journal published by the American Society of Hematology. The cover figure of&
Read morePenn's Gene Therapy Startup Raises Another $50 Million
Funding for cellular therapies that target specific B cells that mediate a wide variety of autoimmune conditions.
Read moreNational Blood Foundation Early-Career Grant for Dr. Vijay Bhoj
Award for research in the fields of transfusion medicine and cellular therapies.
Read moreStem Cell Lab Part of New Treatment for Lung Complications
Nationwide trial using adult stem cells to battle Acute Respiratory Distress Syndrome.
Read more
